Quorum Review IRB Introduces Predictable Subscription Pricing

Share Article

Quorum Review IRB is announcing an innovative subscription-based pricing structure. Subscription pricing will eliminate most challenges associated with budgeting for IRB oversight of clinical trials.

News Image
Some of our clients get caught in a cycle of budget amendments and task order revisions,” says Cami Gearhart, Quorum’s CEO, “with this new pricing model, an accurate budget can be established up front.

Quorum Review IRB is announcing an innovative subscription-based pricing structure. Subscription pricing will eliminate most challenges associated with budgeting for IRB oversight of clinical trials. The result of using Quorum’s subscription pricing will be studies that operate consistently within budget without the delays and hassle of amending budgets.

Budgeting for clinical trials can be complicated. It is difficult to predict the number of amendments that will occur or the amount of participant recruitment material that will be needed. This proactive pricing structure removes the guesswork in today’s clinical trial processes. “Some of our clients get caught in a cycle of budget amendments and task order revisions,” says Cami Gearhart, Quorum’s CEO, “with this new pricing model, an accurate budget can be established up front.”

Under Quorum’s subscription pricing clients simply pay a recurring monthly fee for each active site. The subscription fee includes unlimited amendments and recruitment services. Quorum’s optional safety mass mailing service may be included for an additional monthly fee per active site. This pricing option is available only to studies spanning 13 months or more in the field.

As the first and only IRB offering such a structure, Quorum is taking the industry lead in supporting their customers who use budget-based metrics to meet performance milestones. This latest innovation is a reflection of Quorum’s commitment to be the IRB to whom researchers turn -- when performance matters.

About Quorum Review
Quorum Review is an independent ethics review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing ethics review of drug and device trials since 1992. Quorum oversees research in accordance with U.S. and Canadian human research subject protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report.

Quorum’s best-in-class service and support includes 13 Board meetings each week plus expedited review, 24 hour site review turnaround, 36 hour amendment review turnaround, a secure web portal, and Smart Forms for online submissions. Quorum’s full service offerings include full study review in the US and Canada, a specialized Phase I team, and unique processes for post-approval and registry studies.

Contact:
Sarah Smith
Marketing Manager
Quorum Review IRB
(206) 902-3319
ssmith(at)quorumreview(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sarah J. Smith
Quorum Review IRB
(877) 472.9883 (206) 902-3319
Email >
Visit website